Growth Metrics

Castle Biosciences (CSTL) Depreciation & Amortization (CF) (2018 - 2025)

Historic Depreciation & Amortization (CF) for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $3.8 million.

  • Castle Biosciences' Depreciation & Amortization (CF) rose 776.62% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.8 million, marking a year-over-year increase of 21786.22%. This contributed to the annual value of $16.0 million for FY2024, which is 2974.05% up from last year.
  • Per Castle Biosciences' latest filing, its Depreciation & Amortization (CF) stood at $3.8 million for Q3 2025, which was up 776.62% from $3.4 million recorded in Q2 2025.
  • Over the past 5 years, Castle Biosciences' Depreciation & Amortization (CF) peaked at $29.8 million during Q1 2025, and registered a low of $233000.0 during Q1 2021.
  • Its 5-year average for Depreciation & Amortization (CF) is $4.2 million, with a median of $3.0 million in 2023.
  • As far as peak fluctuations go, Castle Biosciences' Depreciation & Amortization (CF) soared by 82317.6% in 2022, and later soared by 197.13% in 2025.
  • Over the past 5 years, Castle Biosciences' Depreciation & Amortization (CF) (Quarter) stood at $1.5 million in 2021, then soared by 95.8% to $2.8 million in 2022, then increased by 13.48% to $3.2 million in 2023, then skyrocketed by 78.91% to $5.8 million in 2024, then plummeted by 33.84% to $3.8 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $3.8 million for Q3 2025, versus $3.4 million for Q2 2025 and $29.8 million for Q1 2025.